DR. ROBERT LESLIE TALBERT, ROBERT TALBERT
Pharmacy at Floyd Curl Dr, San Antonio, TX
License number
Texas 34891
Category
Pharmacy
Type
Pharmacotherapy
Address
Address
7703 Floyd Curl Dr, San Antonio, TX 78229
Phone
(210) 567-8318
(210) 567-8328 (Fax)
(210) 567-8328 (Fax)
Professional information
Professor At University Of Texas
Position:
Professor at University of Texas, Professor at University of Texas at Austin
Location:
San Antonio, Texas Area
Industry:
Pharmaceuticals
Work:
University of Texas
since 1975
-
Professor
University of Texas at Austin
since 1975
-
Professor
University of Texas
1975 - 2008
-
Professor
Education:
University of Kentucky
Robert L Talbert, San Antonio TX
Specialties:
Pharmacotherapy
Address:
7703 Floyd Curl Dr, San Antonio 78229
(210) 567-8318 (Phone), (210) 567-8328 (Fax)
(210) 567-8318 (Phone), (210) 567-8328 (Fax)
Languages:
English
Enhanced Delivery Of Immunosuppressive Drug Compositions For Pulmonary Delivery
US Patent:
2010018, Jul 22, 2010
Filed:
Jan 10, 2008
Appl. No.:
12/522774
Inventors:
Robert O. Williams - Austin TX, US
Keith P. Johnston - Austin TX, US
Prapasri Sinswat - Austin TX, US
Jason T. McConville - Austin TX, US
Robert Talbert - San Antonio TX, US
Jay I. Peters - San Antonio TX, US
Alan B. Watts - Austin TX, US
True L. Rogers - Midland TX, US
Keith P. Johnston - Austin TX, US
Prapasri Sinswat - Austin TX, US
Jason T. McConville - Austin TX, US
Robert Talbert - San Antonio TX, US
Jay I. Peters - San Antonio TX, US
Alan B. Watts - Austin TX, US
True L. Rogers - Midland TX, US
Assignee:
Board of Regents, The University of Texas System - Austin TX
International Classification:
A61K 9/14, A61K 31/436, A61P 37/00, A61P 11/00
US Classification:
424484, 514291, 977788
Abstract:
The present invention includes compositions and methods for making and using a rapid dissolving, high potency, substantially amorphous nanostructured aggregate for pulmonary delivery of tacrolimus and a stabilizer matrix comprising, optionally, a polymeric or non-polymeric surfactant, a polymeric or non-polymeric saccharide or both, wherein the aggregate comprises a surface area greater than 5 m/g as measured by BET analysis and exhibiting supersaturation for at least 0.5 hours when 11-15-times the aqueous crystalline solubility of tacrolimus is added to simulated lung fluid.
Enhanced Delivery Of Drug Compositions To Treat Life Threatening Infections
US Patent:
2007028, Dec 13, 2007
Filed:
Aug 26, 2005
Appl. No.:
11/660012
Inventors:
James Hitt - Midland MI, US
True Rogers - Midland MI, US
Brian Scherzer - Midland MI, US
Ian Gillespie - Linden MI, US
Paula Garcia - Midland MI, US
Nicholas Beck - Midland MI, US
Christopher Tucker - Midland MI, US
Timothy Young - Bay City MI, US
David Hayes - Midland MI, US
Robert Williams III - Austin TX, US
Keith Johnston - Austin TX, US
Jason McConville - Austin TX, US
Jay Peters - San Antonio TX, US
Robert Talbert - San Antonio TX, US
David Burgess - San Antonio TX, US
True Rogers - Midland MI, US
Brian Scherzer - Midland MI, US
Ian Gillespie - Linden MI, US
Paula Garcia - Midland MI, US
Nicholas Beck - Midland MI, US
Christopher Tucker - Midland MI, US
Timothy Young - Bay City MI, US
David Hayes - Midland MI, US
Robert Williams III - Austin TX, US
Keith Johnston - Austin TX, US
Jason McConville - Austin TX, US
Jay Peters - San Antonio TX, US
Robert Talbert - San Antonio TX, US
David Burgess - San Antonio TX, US
Assignee:
THE DOW CHEMICAL COMPANY - Midland MI
BOARD OF REGENTS UNIVERSITY OF TEXAS SYSTEM - Austin TX
BOARD OF REGENTS UNIVERSITY OF TEXAS SYSTEM - Austin TX
International Classification:
A61K 31/7048, A61K 31/16, A61K 31/4164, A61K 31/4196, A61P 31/00, A61K 31/496, A61K 31/5375
US Classification:
514031000, 514231200, 514254070, 514256000, 514274000, 514383000, 514396000, 514399000, 514599000, 514789000
Abstract:
Inhalable compositions are described. The inhalable compositions comprise one or more respirable aggregates, the respirable aggregates comprising one or more poorly water soluble active agents, wherein at least one of the active agents reaches a maximum lung concentration (C) of at least about 0.25 μg/gram of lung tissue and remains at such concentration for a period of at least one hour after being delivered to the lung. Methods for making such compositions and methods for using such compositions are also disclosed.